Transaldolase deficiency causes a starvation-like response that decreases animal fat content and rewires lipid metabolism gene expression. by Christopher F. Bennett (3875731)

“…<b>(E)</b> RNAi knockdown of <i>tald-1</i> or <i>cco-1</i> causes a decrease in stearoyl-CoA desaturase <i>fat-7p</i>::<i>gfp</i> reporter expression. …”

Reformation of oxygen gradient in a disturbed sediment. by Xuegang Mao (599968)

Subjects:

DHEA decreases the apoptotic loss of TrkA positive sensory neurons in dorsal root ganglia of NGF null mouse embryos. by Iakovos Lazaridis (223341)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Increasing temperature decreases oxygen concentration and decreasing oxygen content decreases neuronal excitability. by Yuguo Yu (172221)

“…Increasing temperature can dramatically decrease oxygen levels. B. Response of layer 2/3 pyramidal cells (n = 5) to the intracellular injection of a depolarizing current pulse (200 pA, 500 ms) at different temperatures (same experiments as in A). …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Effect of OKN-007 on diffusion measured as ADC values in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

Effect of OKN-007 on perfusion rates measured as rCBF in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)